艾司西酞普兰与西酞普兰治疗复发性脑胶质瘤患者焦虑抑郁情绪疗效观察  

Clinical comparative study of Ai Sciplan and citalopram in the treatment of anxiety in patients with recurrent glioma

作　　者：丁吉涛[1] 酒晓莹 王正茂[1] 李明浩[1] DING Jitao;JIU Xiaoying;WANG Zhengmao(Nanyang Second General Hospital of Henan,Nanyang 473000,China)

机构地区：[1]河南省南阳市第二人民医院神经外科

出　　处：《国际精神病学杂志》2019年第4期696-699,共4页Journal Of International Psychiatry

摘　　要：目的观察艾司西酞普兰与西酞普兰治疗复发性脑胶质瘤患者焦虑与抑郁情绪的疗效。方法选取本院2007年7月~2018年2月收治的82例复发性脑胶质瘤患者,按随机数字表分为观察组与对照组,各41例。对照组于术后予西酞普兰进行治疗,观察组口服草酸艾司西酞普兰片,两组均连续口服8周。比较两组治疗前与治疗8周后的焦虑程度与抑郁程度[采用汉密顿焦虑量表(HAMA)与汉密顿抑郁量表(HAMD)进行评估]、不良反应总发生率。结果两组治疗前的HAMA评分与HAMD评分的差异无统计学意义(P>0.05);治疗8周后,两组的HAMA评分与HAMD评分均较治疗前减小,差异有统计学意义(P<0.05)。观察组治疗后的HAMA评分与HAMD评分分别为(9.79±1.99)分与(11.52±2.33)分,低于对照组(13.22±2.34)分与(13.30±2.27)分,差异有统计学意义(P<0.05)。观察组与对照组不良反应总发生率分别为17.07%与12.20%,差异无统计学意义(P>0.05)。结论艾司西酞普兰对5-HT再摄取具有更强抑制作用,对复发性脑胶质瘤患者的焦虑与抑郁症状改善作用优于西酞普兰,且安全性高,为该类患者的理想治疗药物。Objective To observe the effect of escitalopram and citalopram on the treatment of recurrent glioma in patients with anxiety and depression. Methods A total of 82 patients with recurrent glioma admitted to our hospital from July 2007 to February 2018 were randomly divided into observation group and control group,with 41 cases in each group. The control group was treated with citalopram after operation. The observation group received oral escitalopram oxalate tablets. The two groups were given orally for 8 weeks. The degree of anxiety and depression before and after 8 weeks of treatment [assessed by the Hamilton Anxiety Scale(HAMA)and Hamilton Depression Scale(HAMD)],the total incidence of adverse reactions were compared between the two groups. Results There was no significant difference in the HAMA score and HAMD score between the two groups before treatment(P>0.05). After 8 weeks of treatment,the HAMA score and HAMD score of the two groups were lower than those before treatment,and the difference were statistically significant(P<0.05). The HAMA score and HAMD score of the observation group were(9.79±1.99)points and(11.52±2.33)points,respectively,which were lower than(13.22±2.34)points and(13.30±2.27)points in control group,and the difference were statistically significant(P<0.05). The total incidence of adverse reactions in the observation group and the control group were 17.07% and 12.20%,the difference was not statistically significant(P>0.05). Conclusion The escitalopram has a stronger inhibitory effect on 5-HT reuptake,and it is superior to citalopram in improving the symptoms of patients,and it is safe and is an ideal therapeutic drug for such patients.

关 键 词：复发性脑胶质瘤 焦虑 抑郁 艾司西酞普兰 西酞普兰 

分 类 号：R749.053[医药卫生—神经病学与精神病学]